Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over
Description
CONCLUSIONS: Overall, we identified no major safety issues and fewer adverse events following the Novavax COVID-19 vaccination among 65-year-olds and over in Korea.
